AGP
TRVI icon

Artia Global Partners’s Trevi Therapeutics TRVI Stock Holding History

Artia Global Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.2M Buy
2,210,852
+197,250
+10% +$2.87M 7.61% 3
2026
Q1 		$24M Hold
2,013,602
– – 4.81% 5
2025
Q4 		$25.2M Buy
2,013,602
+13,900
+0.7% +$161K 3.57% 7
2025
Q3 		$18.3M Buy
1,999,702
+687,862
+52% +$5.16M 2.9% 12
2025
Q2 		$7.18M Buy
+1,311,840
New +$8.16M 1.73% 12

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Artia Global Partners's TRVI Position: Q2 2026 in Review

Artia Global Partners increased its Trevi Therapeutics (TRVI) stake by 9.8% in Q2 2026, buying an estimated $2.87M and bringing the position to 2,210,852 shares worth $41.2M. The position accounts for 7.61% of the portfolio, ranked #3.

Artia Global Partners first reported a position in TRVI in Q2 2025 and has held it in 5 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Artia Global Partners held 2,210,852 shares of Trevi Therapeutics worth $41.2M as of Q2 2026.
  • Artia Global Partners bought 197,250 Trevi Therapeutics shares in Q2 2026, an estimated $2.87M.
  • Trevi Therapeutics made up 7.61% of Artia Global Partners's portfolio in Q2 2026, its #3 holding.
  • Artia Global Partners first reported a position in Trevi Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.